Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Stanley Chia, MD, MRCP*,
Fred Senatore, MD, PhD, FACC ,
O. Christopher Raffel, MB, ChB, FRACP*,
Hang Lee, PhD ,
Frans J. Th. Wackers, MD, PhD, FACC ,
Ik-Kyung Jang, MD, PhD, FACC*,*
* Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts
Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts
Mitsubishi Pharma America, Warren, New Jersey
Cardiovascular Nuclear Imaging and Stress Laboratories, Yale University School of Medicine, New Haven, Connecticut.
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Time-Concentration Curves for Cardiac Biomarkers
Time-concentration curves for cardiac biomarkers (creatine kinase [CK]-MB, total CK, troponin T, and troponin I) demonstrating release profiles after primary percutaneous coronary intervention.
|
|
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 TnI72h Correlates With Infarct Size and LVEF
Correlation between troponin I levels taken at 72 h (TnI72h) after admission and single-photon emission computed tomography (SPECT)-determined myocardial infarct size and left ventricular ejection fraction (LVEF) on Day 5.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Cumulative Event-Free Survival Stratified by TnI72h
Kaplan-Meier estimates of survival free of composite clinical end points among patients stratified by plasma troponin I concentrations taken at 72 h (TnI72h).
|
|
|
